-

01:58:30 PM

CALT Stock News

CALT - Calliditas Therapeutics AB

05/19/22 10:45 AM

Nasdaq : CALT

low float

Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)

The meeting was held in accordance with sections §§ 20 and 22 of the Act (2022:121) on temporary exceptions to facilitate the execution of general meetings in companies and other associations and the shareholders solely exercised their voting rights at the

RHEA-AI

neutral

05/19/22 8:41 AM

Nasdaq : CALT

low float

Calliditas receives positive CHMP opinion in IgA nephropathy

Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the granting of a

RHEA-AI

very positive

05/18/22 1:30 AM

Nasdaq : CALT

low float

Calliditas Therapeutics: Interim Report Q1, 2022

Start of TARPEYO™ Commercial Launch in the US "During the first quarter Calliditas launched its first commercial product, TARPEYO, in the US, supported by 40 experienced specialty sales executives who were trained and in the field in late January. Our

RHEA-AI

positive

05/17/22 5:15 AM

Nasdaq : CALT

clinical triallow float

First patient randomized in Phase 2 trial in head and neck cancer

Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the first patient has been randomized in the company's proof-of-concept Phase 2 study in patients with squamous cell carcinoma of the head and neck

RHEA-AI

neutral

05/14/22 8:00 AM

Nasdaq : CALT

low float

Calliditas Therapeutics Launches an Online Patient Platform

Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced the launch of IgAN Connect, a new online platform to provide resources to people living

RHEA-AI

neutral

05/10/22 2:43 AM

Nasdaq : CALT

conferenceslow float

Calliditas Therapeutics to participate in upcoming investor conferences

Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that its management team will participate in the following upcoming investor conferences and events:The 8 th Annual LSX World Congress on May 10-11, 2022 in

RHEA-AI

neutral

04/29/22 4:16 AM

Nasdaq : CALT

low float

Number of shares and votes in Calliditas Therapeutics

During April, Calliditas Therapeutics AB (publ) has allotted 830,586 common shares within the company's warrant program issued in 2018. Thus, as of April 29, 2022, the number of shares and votes in the company amounts to 53,172,170.For further information,

RHEA-AI

neutral

04/27/22 12:11 PM

Nasdaq : CALT

low float

Calliditas Therapeutics' 2021 Annual Report Published

Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) today announces that the Annual Report for 2021 now is available at the company's website: www.calliditas.com.This information is information that Calliditas Therapeutics AB is obliged to

RHEA-AI

neutral

04/14/22 3:28 AM

Nasdaq : CALT

low float

Notice of annual general meeting of Calliditas Therapeutics AB (publ)

The shareholders of Calliditas Therapeutics AB (publ), Reg. No. 556659-9766, with registered office in Stockholm, are summoned to the annual general meeting on Thursday 19 May 2022.With reference to the Swedish Act (2022:121) on temporary exceptions to

RHEA-AI

very positive

03/24/22 7:10 AM

Nasdaq : CALT

acquisitionlow float

Calliditas CEO acquires shares through the exercise of Calliditas' warrant program 2018/2022

Calliditas Therapeutics AB (publ) (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") announced today that CEO Renée Aguiar-Lucander has subscribed for 175,000 shares through Calliditas' warrant program 2018/2022. Following the new subscription for

RHEA-AI

neutral

1 2 3 4 5 6 7 8 Next